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Abstract
Background: Artemisinin-based combination therapy (ACT) is widely recommended as first-line therapy for
uncomplicated Plasmodium falciparum malaria worldwide. Artemisinin resistance has now been reported in
Southeast Asia with a clinical phenotype manifested by slow parasite clearance. Although there are no reliable
reports of artemisinin resistance in Africa, there is a need to better understand the dynamics of parasite clearance in
African children treated with ACT in order to better detect the emergence of artemisinin resistance.
Methods: Data from a cohort of Ugandan children four to five years old, enrolled in a longitudinal, randomized,
clinical trial comparing two leading ACT, artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP),
were analysed. For all episodes of uncomplicated P. falciparum malaria over a 14-month period, daily blood smears
were performed for three days following the initiation of therapy. Associations between pre-treatment variables of
interest and persistent parasitaemia were estimated using multivariate, generalized, estimating equations with
adjustment for repeated measures in the same patient.
Results: A total of 202 children were included, resulting in 416 episodes of malaria treated with AL and 354
episodes treated with DP. The prevalence of parasitaemia on days 1, 2, and 3 following initiation of therapy was
67.6, 5.6 and 0% in those treated with AL, and 52.2, 5.7 and 0.3% in those treated with DP. Independent risk factors
for persistent parasitaemia on day 1 included treatment with AL vs DP (RR = 1.34, 95% CI 1.20-1.50, p < 0.001),
having a temperature ≥38.0°C vs < 37.0°C (RR = 1.19, 95% CI 1.05-1.35, p = 0.007) and having a parasite
density >20,000/μL vs <4,000/μL (RR = 3.37, 95% CI 2.44-4.49, p < 0.001). Independent risk factors for having
persistent parasitaemia on day 2 included elevated temperature, higher parasite density, and being HIV infected.
Conclusions: Among Ugandan children, parasite clearance following treatment with AL or DP was excellent with
only one of 752 patients tested having a positive blood slide three days after initiation of therapy. The type of ACT
given, pre-treatment temperature, pre-treatment parasite density and HIV status were associated with differences in
persistent parasitaemia, one or two days following therapy.
Trial registration: Current Controlled Trials Identifier NCT00527800.
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Background
Artemisinin-based combination therapy (ACT) is cur-
rently recommended for the treatment of uncomplicated
Plasmodium falciparum malaria by the World Health
Organization and has been adopted as first-line therapy
in most malaria-endemic countries [1]. Marked reductions
in malaria-associated morbidity and mortality in many
parts of the world have been attributed to the replacement
of failing monotherapies with highly effective ACT and the
scale-up of vector control measures [2]. However the re-
cent emergence and/or spread of artemisinin resistance in
parts of Southeast Asia [3-6] poses a serious threat to mal-
aria control efforts. Although artemisinin resistance has
not yet been reported in Africa, there is a historical prece-
dence of resistance to older monotherapies emerging in
Asia and spreading to Africa with devastating effects [7-9].
Thus early and accurate detection of artemisinin resist-
ance in African populations will be critical for the imple-
mentation of containment efforts.
The phenotype of artemisinin resistance is character-
ized by a significant delay in parasite clearance following
initiation of therapy [3-6]. As there are no reliable mo-
lecular markers of resistance and in vitro correlates have
been inconsistent [10], surveillance of artemisinin resist-
ance to date has relied on in vivo studies to measure
early clearance of peripheral parasitaemia by microscopy.
The use of sampling multiple times a day at measured
time points to estimate the rate of parasite clearance has
been proposed as an accurate and reliable method for
the early detection of artemisinin resistance [11]. However,
this approach may be difficult to implement in settings of
routine in vivo drug efficacy studies among outpatients.
An alternative approach is to measure the proportion of
patients with detectable parasitaemia one, two or three
days after the initiation of therapy [12,13]. Although this
alternative approach is simple to implement, there are
multiple factors that could be associated with parasite
clearance independent of artemisinin resistance, which
may confound the interpretation of results.
In this study the proportion of patients with detectable
parasitaemia one, two and three days after initiation of
therapy were measured in a cohort of Ugandan children
randomized to two different ACT regimens. The objective
of the study was to identify factors associated with early
parasite clearance in a setting where artemisinin resistance
has not yet occurred. This information will be important
for the interpretation of future surveillance studies aimed
at identifying early signs of artemisinin resistance in
African populations.
Methods
Study design, site and population
This study was part of a larger open-label, randomized
trial conducted at Tororo, an area in Eastern Uganda with
high malaria transmission intensity [14]. The methods of
the main study have been described previously [15,16].
Briefly, convenience sampling was used to enrol a cohort
of HIV infected and uninfected children referred to a
dedicated study clinic from an adjacent post-natal clinic
at Tororo District Hospital. Eligibility criteria included:
1) age six weeks to 12 months, 2) documented HIV status
of mother and child, 3) agreement to come to the study
clinic for any febrile episode or other illness, 4) residence
within a 30-km radius of the study clinic, 5) absence of
active medical problem requiring inpatient evaluation at
the time of screening, and, 6) provision of informed
consent. At enrolment, all study participants received a
long-lasting, insecticide-treated bed net (ITN).
Follow-up of study participants
Subjects were followed for all of their medical prob-
lems at a dedicated study clinic open seven days a week
and parents/guardians were encouraged to bring their
children to the study clinic whenever they were ill. HIV-
infected children were prescribed daily trimethoprim-
sulphamethoxazole (TS) prophylaxis. Medications with
anti-malarial activity were avoided for the treatment of
non-malarial illnesses. Study participants were followed
until they reached five years of age or met one of the fol-
lowing criteria for early study withdrawal: 1) movement
out of the study area, 2) inability to be located for >60
consecutive days, 3) withdrawal of informed consent,
4) inability to adhere to the study schedule and proce-
dures, or, 5) inability to tolerate the drugs used for malaria
treatment.
Malaria diagnosis and treatment
Children who presented to the study clinic with a docu-
mented fever (tympanic temperature ≥38.0˚C) or history of
fever in the previous 24 hours had blood obtained by finger
prick for a thick smear. If the thick smear was positive, the
patient was diagnosed with malaria regardless of parasite
density. Children who were aged ≥ four months and weigh-
ing ≥5 kg were randomized to receive either artemether-
lumefantrine (AL) or dihydroartemisinin-piperaquine (DP)
at the time they got their first episode of uncomplicated
malaria. Study participants received the same treatment
regimen for all subsequent episodes of uncomplicated
malaria. Study drugs were given according to weight-
based guidelines for fractions of tablets as follows: AL
(tablets of 20 mg of artemether and 120 mg of lumefan-
trine; Coartem; Novartis), administered as one (5–14 kg)
or two (15–24 kg) tablets given twice daily for three days;
and DP (tablets of 40 mg of dihydroartemisinin and
320 mg of piperaquine; Duocotecxin; Holley Pharm), tar-
geting a total dose of 6.4 and 51.2 mg/kg of dihydroarte-
misinin and piperaquine, respectively, given in three
equally divided daily doses to the nearest one-quarter
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tablet. Study drugs were crushed, mixed with water and
administered to the patient. Patients were given a glass of
milk after each dose. The first daily dose of study drugs
was directly observed at the study clinic. After each dose,
children were observed for 30 minutes, and the dose was
re-administered if vomiting occurred. For children treated
with AL, the second daily dose was packaged and the
parent or guardian was given verbal instructions for
proper administration of the medication at home with
clear emphasis on when the evening dose should be
given. Episodes of complicated malaria and treatment
failures occurring within 14 days of initiating treatment
were treated with quinine. All children with malaria were
followed up on days 1, 2, 3, 7, 14, 21, and 28 following
enrolment.
Laboratory methods
Thick and thin blood smears were stained with 2% Giemsa
for 30 minutes and read by trained laboratory technolo-
gists who were not involved in direct patient care. Parasite
densities were calculated from thick blood smears by
counting the number of asexual parasites per 200 leuko-
cytes (or per 500 leukocytes, if the count was <10 asexual
parasites/200 leukocytes), assuming a leukocyte count of
8,000/μl. A blood smear was considered negative when
the examination of 100 high power fields did not reveal
asexual parasites. For quality control, all slides were read
by a second reader. An independent third reader settled
any discrepancies between the first and second readings.
Laboratory technicians were blinded to the study partici-
pants’ treatment assignments. Thin smears were used to
determine the parasite species.
Statistical methods
Data were double entered into an Access database and
analysed using Stata version 11 (Stata Corp, College
Station, TX, USA). This study included only data from
episodes of uncomplicated P. falciparum malaria diag-
nosed between October 2011 and December 2012 when
routine blood smears were added on day 1 of malaria
follow-up. During this period, all children remaining in
the cohort study were between 47 and 60 months of age.
The primary outcome of interest was the proportion of
patients who remained parasitaemic by microscopy one,
two and three days following initiation of therapy. Sec-
ondary outcomes included persistence of fever (either
subjective fever in the previous 24 hours or tympanic
temperature ≥38.0°C,) during the first three days follow-
ing initiation of therapy and 28-day standardized WHO
treatment outcomes unadjusted by genotyping. The
treatment outcomes were classified as: adequate clinical
and parasitological response (all blood smears negative
after day 3); early treatment failure (presence of danger
signs or complicated malaria with a positive blood smear
within three days of treatment, or day 2 parasite density >
day 0 parasite density, or day 3 parasite density >25% of
day 0 parasite density, or positive blood smear on day 3
with a tympanic temperature ≥38.0°C); late clinical failure
(first positive blood smear after day 3 in the presence of
fever); and late parasitological failure (first positive blood
smear after day 3 in the absence of fever). Risk factors of
interest included the ACT regimen (AL vs DP); mg/kg
dosing of anti-malarials; treatment episode number; pre-
treatment temperature, parasite density and haemoglobin;
age; gender; and HIV status. We explored the relationship
between pre-treatment parasite density and proportion
with parasitaemia and it was nonlinear. We thus created a
categorical variable for parasite density to create the most
parsimonious model that best fit the distribution of the
data. Associations between risk factors of interest and
early persistent parasitaemia were estimated using general-
ized estimating equations with robust standard errors and
adjustment for repeated measures in the same patient.
Risk factors associated with the outcome of interest with a
p-value of < 0.05 in univariate analyses were included in
the final multivariate model, with the exception of age and
gender which were also included.
Ethical approval
Informed consent was obtained from the parents or legal
guardian of all study participants. The study protocol was
approved by the Uganda National Council of Science and
Technology and the institutional review boards of the
University of California, San Francisco, Makerere Univer-
sity, the University of Washington, and the Centers for
Disease Control and Prevention.
Results
Study profile and characteristics of the malaria episodes
A total of 787 episodes of malaria were treated in 202
study participants during the study period of October
2011 to December 2012. Three episodes of complicated
malaria treated with quinine and 14 episodes of malaria
caused by non-falciparum species were excluded from the
analysis (Figure 1). Of 770 uncomplicated malaria episodes
due to P. falciparum, 416 episodes were treated with AL
and 354 episodes were treated with DP. The mean age,
temperature, and haemoglobin level was similar in both
treatment arms (Table 1). Episodes treated with DP had a
higher parasite density compared to those treated with AL
(20,295 vs 13,258 parasites/μl, p = 0.004). A total of 38
(4.9%) episodes occurred in HIV-infected children and
were equally distributed between the two treatment arms.
Malaria treatment outcomes
On day one following initiation of anti-malarial treatment,
a total of 450 of 745 (60.4%) episodes with blood smears
done had persistent asexual parasitaemia by microscopy
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and the prevalence was higher in those treated with AL
compared to DP (67.6 vs 52.2%, p < 0.001). On day two
following initiation of anti-malarial treatment, a total of 43
of 764 (5.6%) episodes with blood smears done had per-
sistent asexual parasitaemia by microscopy and the preva-
lence was similar between the two ACT treatment arms.
On day three following initiation of anti-malarial treat-
ment, only one of 752 (0.1%) episodes with blood smears
done had persistent parasitaemia (Table 2). This patient
was treated with DP and had a parasite density of only 16
asexual parasites/μL on day three which cleared by day
seven when the next blood smear was done.
Patients treated with AL were more likely to be febrile
on day 1 following initiation of anti-malarial treatment
compared to those treated with DP (30 vs 18.4%, re-
spectively, P = 0.002). There was no significant difference
between the two ACT treatment arms in the prevalence
of fever on day two and three following initiation of anti-
malarial therapy (Table 2). Considering 28-day WHO
treatment outcomes, there was only one early treatment
failure, which occurred in a patient treated with DP due to
an increase in the parasite density from 12,720 asexual
parasites/μL on day 0 to 18,960 asexual parasites/μL on
day two. Interestingly, when this patient returned to clinic
on day three the blood smear was negative and therefore
rescue therapy was not given. Patients treated with DP
were significantly more likely to have an adequate clinical
and parasitological response compared to those treated
with AL (87.9 vs 45.4%, p < 0.001) (Table 2).
Figure 1 Trial profile. AL = artemether-lumefantrine,
DP = dihydroartemisinin-piperaquine.
Table 1 Baseline characteristics of all episodes of
uncomplicated falciparum malaria
Characteristic Treatment arm
AL (n = 416) DP (n = 354)
Patient age in months,
mean (range)
56 (48–60) 56 (47–60)
Gender, number female (%) 210 (50.5) 141 (39.8)
Dosing of artemisinin drug
in mg/kg, median (range)
14.3 (8.3-16.6) 7.2 (5.8-8.5)
Dosing of partner drug in
mg/kg, median (range)
85.7 (50.0-99.3) 57.5 (46.2-67.9)
Temperature °C, mean (SD) 37.6 (1.0) 37.7 (1.0)
Parasite density per μL,
geometric mean
13,258 20,295
Haemoglobin g/dL,
mean (SD)
11.1 (1.5) 11.2 (1.5)
HIV infected, n (%) 18 (4.3%) 20 (5.7%)
Treatments per child, median (range) 3 (1–13) 2 (1–13)
Table 2 Response to anti-malarial therapy
Characteristic Treatment arm p-value
AL (n = 416) DP (n = 354)
Parasite persistence, n (%)
Positive blood smear day 1 269 (67.6%) 181 (52.2%) <0.001
Positive blood smear day 2 23 (5.6%) 20 (5.7%) 0.92
Positive blood smear day 3 0 1 (0.3%) N/A
Fever persistence, n (%)
Febrile* day 1 124 (30.0%) 65 (18.4%) 0.002
Febrile* day 2 8 (1.9%) 11 (3.1%) 0.28
Febrile* day 3 7 (1.7%) 7 (2.0%) 0.78
28-day WHO treatment
outcome, n (%)
Lost to follow-up 16 (3.9%) 13 (3.7%)
Early treatment failure 0 1 (0.3%)
Late parasitological failure 137 (32.9%) 22 (6.2%) < 0.001
Late clinical failure 74 (17.8%) 7 (2.0%)
Adequate clinical and
parasitological response
189 (45.4%) 311 (87.9%)
*Subjective fever in the previous 24 hours or temperature ≥38.0°C (tympanic).
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Risk factors associated with a persistent parasitaemia on
days one and two following initiation of anti-malarial
therapy
In univariate analyses, the anti-malarial treatment regi-
men administered, pre-treatment temperature, and pre-
treatment parasite density were significantly associated
with persistent parasitaemia on day one following initi-
ation of anti-malarial therapy. In the final multivariate
model the following factors were significantly associated
with an increased risk of persistent parasitaemia on day
one: treatment with AL compared to DP (RR = 1.34, 95%
CI 1.20-1.50, p < 0.001); pre-treatment temperature ≥38.0
compared to <37.0 (RR = 1.19, 95% CI 1.05-1.35, p = 0.007);
and pre-treatment parasite density >20,000/μL (RR = 3.31,
95% CI 2.44-4.49, p < 0.001) and 4,000-20,000/μL (RR =
2.61, 95% CI 1.89-3.59, p < 0.001) compared to <4,000/μL
(Table 3). In univariate analyses pre-treatment temperature,
pre-treatment parasite density, and HIV status were sig-
nificantly associated with persistent parasitaemia on day
two following initiation of anti-malarial therapy. In the
final multivariate model the following factors were signifi-
cantly associated with an increased risk of persistent para-
sitaemia on day two: pre-treatment temperature ≥37.0
(RR = 2.32, 95% CI 1.00-5.38, p = 0.049); pre-treatment
parasite density >20,000/μL (RR = 5.09, 95% CI 2.19-11.9,
p < 0.001); and being HIV infected (RR = 3.93, 95% CI
1.74-8.88, p = 0.001) (Table 4).
Discussion
In this study of 770 episodes of uncomplicated falciparum
malaria in Ugandan children randomized to therapy with
AL or DP, parasite clearance was excellent with only one
episode of parasitaemia documented by microscopy three
days after initiation of therapy. To better understand the
dynamics of early parasite clearance following ACT
treatment in an African setting without evidence of ar-
temisinin resistance, several risk factors associated with
persistent parasitaemia one and two days after initiation
of therapy were identified. Considering persistent para-
sitaemia on day one, treatment with AL compared to DP,
an elevated pre-treatment temperature, and higher pre-
treatment parasite density, were independently associated
with a significantly increased risk of persistent parasit-
aemia. Considering persistent parasitaemia on day two, an
elevated pre-treatment temperature, higher pre-treatment
parasite density and being HIV infected were independ-
ently associated with a significantly increased risk of per-
sistent parasitaemia.
The rationale behind ACT is based on the highly potent,
but short-acting artemisinin component causing rapid
Table 3 Associations between variables of interest and a positive blood slide on day 1
Variable Categories Risk of positive blood
smear on day 1
Univariate analysis Multivariate analysis
RR* (95% CI) p-value RR† (95% CI) p-value
Anti-malarial treatment DP 52.2% 1.0 (reference) - 1.0 (reference) -
AL 67.6% 1.30 (1.13-1.49) <0.001 1.35 (1.21-1.50) <0.001
mg/kg dosing of anti-malarial ≥ median (DP) 55.0% 1.0 (reference) - Not included in final model
< median (DP) 49.4% 0.96 (0.78-1.18) 0.68
≥ median (AL) 64.3% 1.0 (reference) -
< median (AL) 70.7% 1.11 (0.96-1.28) 0.16
Temperature °C < 37.0 48.2% 1.0 (reference) - 1.0 (reference) -
37.0-37.9 59.7% 1.22 (1.03-1.44) 0.02 1.09 (0.96-1.24) 0.19
≥ 38.0 71.2% 1.47 (1.25-1.73) <0.001 1.17 (1.04-1.33) 0.01
Parasite density per μL < 4,000 21.3% 1.0 (reference) - 1.0 (reference) -
4,000-20,000 57.4% 2.64 (1.93-3.63) <0.001 2.62 (1.90-3.62) <0.001
> 20,000 73.5% 3.39 (2.51-4.59) <0.001 3.31 (2.44-4.49) <0.001
Haemoglobin g/dL ≥ 10 60.0% 1.0 (reference) - Not included in final model
< 10 64.0% 1.08 (0.92-1.26) 0.33
HIV status Negative 60.5% 1.0 (reference) - Not included in final model
Positive 58.3% 0.97 (0.72-1.31) 0.84
Episode number 1-2 59.9% 1.0 (reference) Not included in final model
3-4 57.1% 0.94 (0.82-1.09) 0.42
≥ 5 65.0% 1.02 (0.90-1.17) 0.74
*Relative risk using generalized estimating equations with adjustment for repeated measures in the same patient.
†Relative risk using generalised estimating equations with adjustment for repeated measures in the same patient, age and gender.
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reduction in peripheral parasitaemia followed by the
longer-acting partner drug eliminating any remaining
parasites [17]. ACT has now become one of the most ef-
fective tools for malaria control and the emergence of
resistance to the artemisinin class of anti-malarial drugs
would pose a major global health problem. Artemisinin
resistance was first reported in Western Cambodia and
has now emerged or spread to other areas of Southeast
Asia [3-6]. Currently the only way to identify artemisi-
nin resistance is through the detection of phenotypic
trait of delayed parasite clearance in vivo following the
initiation of therapy. Thus, there is great interest in sur-
veillance studies of early parasite clearance to provide an
“early warning system” for the emergence/spread of arte-
misinin resistance in areas where this has not be previ-
ously documented. However, accurate characterization of
the clinical phenotype of delayed parasite clearance may
be complicated by a number of factors acting independent
of artemisinin resistance, such as drug concentrations,
pharmacodynamics properties of the partner drug, pre-
treatment parasite density, and host immunity.
In this study, a number of factors were independently
associated with persistent parasitaemia on days one and
two following the initiation of ACT. A higher pre-
treatment parasite density had the strongest association
with persistent parasitaemia on days one and two. This
finding is expected given that time to parasite clearance is
a function of the baseline parasite density [18]. Thus any
assessment of early parasite clearance should account for
the pre-treatment parasite density. One method proposed
to account for pre-treatment parasite density is to estimate
the parasite clearance rate, as defined by the slope of the
linear portion of the natural logarithm of the parasite
clearance curve, rather than simply the proportion of
patients who remain parasitaemic following the initiation
of therapy [11]. However, this method requires frequent
sampling, ideally every six to eight hours or at least every
12 hours until parasite clearance, which may pose consid-
erable challenges in the setting of routine drug efficacy
surveillance studies. For clinical studies that continue to
rely on less frequently sampling and determine the pro-
portion of patients who remain parasitaemic at different
time points, control of pre-treatment parasite density will
be essential for monitoring trends in early parasite clear-
ance over time and space.
In this study a higher pre-treatment temperature was
also associated with persistent parasitaemia on days one
and two. This finding has been reported in another study
from Kenya [19] and may be a surrogate marker of a less
effective host immune response. In addition, infection
with HIV was associated with persistent parasitaemia on
day two in this study, providing further evidence of the
Table 4 Associations between variables of interest and a positive blood slide on day 2
Variable Categories Risk of positive blood
smear on day 2
Univariate analysis Multivariate analysis
RR* (95% CI) p-value RR† (95% CI) p-value
Anti-malarial treatment DP 5.7% 1.0 (reference) - Not included in final model
AL 5.6% 1.03 (0.55-1.95) 0.92
mg/kg dosing of anti-malarial ≥ median (DP) 5.8% 1.0 (reference) - Not included in final model
< median (DP) 5.6% 1.00 (0.41-2.43) 0.99
≥ median (AL) 4.0% 1.0 (reference) -
< median (AL) 7.1% 1.74 (0.70-4.38) 0.23
Temperature °C < 37.0 2.6% 1.0 (reference) - 1.0 (reference) -
37.0-37.9 5.9% 2.35 (0.98-5.59) 0.05 2.32 (1.01-5.31) 0.048
≥ 38.0 7.8% 3.09 (1.28-7.46) 0.01
Parasite density per μL < 4,000 1.4% 1.0 (reference) - 1.0 (reference) -
4,000-20,000 1.3%
> 20,000 8.3% 5.79 (2.35-14.3) <0.001 5.12 (2.12-12.37) <0.001
Haemoglobin g/dL ≥ 10 5.4% 1.0 (reference) - Not included in final model
< 10 6.0% 1.06 (0.46-2.45) 0.89
HIV status Negative 5.0% 1.0 (reference) - 1.0 (reference) -
Positive 19.4% 3.87 (1.85-8.12) <0.001 3.69 (1.54-8.84) 0.003
Episode number 1-2 6.9% 1.0 (reference) - Not included in final model
3-4 5.1% 0.74 (0.37-1.48) 0.39
≥5 3.7% 0.50 (0.20-1.29) 0.15
*Relative risk using generalized estimating equations with adjustment for repeated measures in the same patient.
†Relative risk using generalized estimating equations with adjustment for repeated measures in the same patient, age and gender.
Muhindo et al. Malaria Journal 2014, 13:32 Page 6 of 8
http://www.malariajournal.com/content/13/1/32
role of the host immune response on early parasite clear-
ance. HIV infection has been associated with an increased
incidence of malaria [20] and increased risk of re-infection
following therapy [21]. In a small study from Ethiopian
adults, HIV-infected patients had a higher risk of persist-
ent parasitaemia 32 hours after the initiation of artemisi-
nin monotherapy compared to HIV-uninfected patients
(six of seven vs two of 12, p = 0.003) [22]. Age has also
been used as a surrogate marker of anti-malarial immunity
and would be expected to influence early parasite clear-
ance. Although the age range for patients enrolled in this
study was too narrow for evaluation, other studies have
reported associations between younger age and persistent
parasitaemia [12,23].
Although early parasite clearance is predominantly a
function of artemisinin activity, different formulations of
the artemisinin component and partner drugs used in
various ACT may also influence early parasite clearance.
In this study, treatment with AL was associated with a
higher risk of persistent parasitaemia on day one com-
pared to treatment with DP. This finding appears to have
some clinical significance as persistent fever on day one
was also higher in patients treated with AL compared to
DP. Similar findings of a higher risk of persistent parasit-
aemia on day one in AL compared to DP have also been
reported in a study from Kenya [19] as well as a large
meta-analysis of studies from Asia and Africa [12].
There were several limitations to this study. As men-
tioned earlier, blood smear samples were obtained once
daily, therefore, it was not possible to accurately estimate
the parasite clearance rate as a continuous variable. This
study also included patients across a narrow age range
(47–60 months) and over a relatively short period of cal-
endar time, thus it was not possible to evaluate age as a
potential risk factor or temporal trends in early parasite
clearance. Finally, only DP was fully administered as dir-
ectly observed therapy, as it was given once daily when
a child presented to the study clinic. In contrast, AL
was given twice daily and only one of the two daily
doses was directly observed. If the second dose of AL
was not appropriately administered at home, differences
in parasite clearance between AL and DP may have been
overestimated.
In summary, results from this study provide reassuring
evidence that among children living in an area of high
malaria endemicity in Uganda, parasite clearance follow-
ing treatment with AL and DP was excellent. To provide a
“baseline” assessment of the dynamics of early parasite
clearance in this study population, several factors were
associated with persistent parasitaemia at days one and
two after the initiation of therapy, including pre-treatment
parasite density, pre-treatment temperature, which ACT
was given, and HIV status. In order to accurately detect
temporal changes in early parasite clearance associated
with the emergence of artemisinin resistance in Africa,
analyses should control for these risk factors and poten-
tially others when comparing data across studies. Finally,
studies with richer parasite density sampling may be re-
quired to model the optimum parasite density sampling
approaches (daily, six, eight or 12 hourly) to robustly track
changes in early parasite clearance in Africa.
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